Poor
Not Aligned
Patient Risk:
Medium
Summary
Many extracted claims are not supported by the provided FDA label excerpts (especially Xgeva-related indications, dosing, and multiple safety/clinical-statements). Several claims also introduce non-label content (pricing, coverage, patents), which cannot be verified against prescribing information.
Category Scores
Accurate Statements
Prolia (denosumab) treats postmenopausal osteoporosis.
Supported by 1 INDICATIONS AND USAGE (per provided evaluation).
Prolia is given as a 60 mg subcutaneous injection every 6 months.
Partially supported by 2 DOSAGE AND ADMINISTRATION (per provided evaluation).
Prolia costs around $1,500 per dose given every 6 months.
Not label-supported / not applicable to FDA labeling excerpts.
The prescribing information should be consulted for pregnancy, renal impairment, or dental risks.
Partially supported by 4 CONTRAINDICATIONS and 5 WARNINGS AND PRECAUTIONS (general referencing).
Unsupported Statements
Prolia (denosumab) increases bone mass in men with osteoporosis.
Not supported by the provided label excerpt set / evaluated as absent from label.
Prolia (denosumab) prevents fractures in patients with glucocorticoid-induced osteoporosis.
Evaluated as absent from the label.
Prolia (denosumab) prevents fractures in patients with bone loss from certain cancer treatments.
Evaluated as absent from the label.
Xgeva (denosumab) prevents bone fractures in adults with bone metastases from solid tumors.
Evaluated as absent from the label.
Xgeva (denosumab) prevents spinal cord compression in adults with bone metastases from solid tumors.
Evaluated as absent from the label.
Xgeva (denosumab) treats giant cell tumor of bone in adults.
Evaluated as absent from the label.
Xgeva (denosumab) treats giant cell tumor of bone in some adolescents when surgery is not an option.
Evaluated as absent from the label.
Xgeva is given as a 120 mg subcutaneous injection every 4 weeks.
Evaluated as absent from the label.
Both Prolia and Xgeva contain denosumab.
No label citation provided in the available excerpts; evaluated as not checked by citation.
Denosumab is a monoclonal antibody that inhibits osteoclast activity.
Evaluated as absent from the label despite citing clinical pharmacology; not supportable from provided excerpt basis.
Prolia formulation is 60 mg/1.7 mL.
Evaluated as absent from the label; excerpt shows 60 mg/mL but does not establish 1.7 mL volume.
Xgeva formulation is 120 mg/1.7 mL.
Evaluated as absent from the label; excerpt does not support this.
Prolia and Xgeva are not interchangeable due to formulation differences and distinct FDA approvals.
No label citation provided; evaluated as absent.
Prolia and Xgeva both carry risks including hypocalcemia.
Evaluated as absent from the label (despite citations), based on provided evaluation status.
Prolia and Xgeva both carry risks including jaw osteonecrosis (ONJ).
Evaluated as absent from the label.
Prolia and Xgeva both carry risks including atypical femur fractures.
Evaluated as absent from the label.
Prolia and Xgeva both carry risks including infections.
Evaluated as absent from the label (for the joint claim).
Xgeva reports higher ONJ rates than Prolia (about 2% vs. 0.04%).
Exact incidence percentages not supportable from provided label excerpt basis; evaluated as absent.
Xgeva links to fatigue and anemia.
No label citation provided; evaluated as absent.
Calcium supplementation and vitamin D supplementation is required for both Prolia and Xgeva.
No label citation provided; evaluated as absent.
Prolia users more often experience back pain or extremity pain.
Only partially supported; comparative/“more often” phrasing is not fully label-grounded in the provided excerpt.
Switching between Prolia and Xgeva requires physician oversight due to dosing differences and monitoring needs.
No label citation provided; evaluated as absent.
Off-label use of Prolia can occur in cancer settings.
Not part of FDA prescribing information in the provided label excerpts; evaluated as absent.
Guidelines recommend using the indicated product rather than switching off-label.
No FDA label support provided; evaluated as absent.
No generic or biosimilar versions exist yet for Prolia or Xgeva.
Not a labeling element; evaluated as absent.
No U.S. patents expire before 2025 for either Prolia or Xgeva.
Not a labeling element; evaluated as absent.
Cancer patients often get Xgeva covered under medical benefits.
Non-label payer/coverage claim; not supported by prescribing information.
Osteoporosis patients may face higher out-of-pocket for Prolia.
Non-label financial claim; not supported by prescribing information.
Contradictions
Important Omissions
For multiple joint safety-risk assertions (e.g., hypocalcemia, ONJ, atypical femur fractures, infections), the label excerpts provided do not substantiate that the same risks apply to both Prolia and Xgeva. If the response intended those as label-supported for both products, it should cite the corresponding Xgeva labeling sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several safety-critical or dosing-critical claims (notably Xgeva indication/dosing and comparative incidence figures; calcium/vitamin D being required for both; and interchangeability/switching oversight) are not supported by the supplied label excerpts, which could mislead risk communication or administration decisions if used as label-accurate guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large portions of the extracted claims are not supported by the provided FDA label excerpts (especially Xgeva indications and dosing, and multiple safety/monitoring assertions). Additionally, non-label claims (pricing, insurance coverage, patents) are included.
Suggested Improvement
Restrict claims to sections explicitly present in the provided labeling excerpt set and add precise citations for each safety/indication/dosing statement. Remove non-label content (pricing/coverage/patents) and avoid joint (Prolia+Xgeva) safety assertions unless both are supported by the provided label text for each product.